Gault Cheryl 4

What Happened Cheryl Gault, COO of Rapport Therapeutics (RAPP), sold a total of 10,000 common shares in open-market transactions on March 30, 2026 for aggregate proceeds of approximately $281,857. The sales occurred in two tranches: 7,161 shares reported at a weighted-average price of $28.04 for $200,795, and 2,839 shares reported at a weighted-average price of $28.55 for $81,062. These were sales (not purchases), which are typically routine dispositions rather than bullish signals.

Key Details

• Transaction dates: March 30, 2026 (filed March 31, 2026 — no late filing indicated).
• Tranche 1: 7,161 shares; weighted-average price $28.04; proceeds $200,795; per-footnote range $27.42–$28.41.
• Tranche 2: 2,839 shares; weighted-average price $28.55; proceeds $81,062; per-footnote range $28.42–$28.72.
• Executed pursuant to a Rule 10b5-1 trading plan adopted December 10, 2025 (prearranged trading plan).
• The filing notes the prices shown are weighted averages and the Reporting Person will provide, upon request, the number of shares sold at each separate price.
• Shares owned after the transactions are not specified in the provided excerpt — see the full Form 4 for post-transaction holdings.

Context These sales were executed under a pre-established 10b5-1 plan, which generally means the trades were scheduled in advance and may not reflect the insider’s current view of the company. For retail investors, purchases by insiders tend to carry more informational weight than routine sales; treat 10b5-1 sales as compliance-driven unless other information indicates otherwise.